Recent News

StiRx Announces Appointment of Harvard Immunologist Michael Starnbach, PhD, to Scientific Advisory Board

Boston, MA — March 2026. StiRx today announced that Michael Starnbach, PhD, Professor of Microbiology and Immunobiology at Harvard Medical School, has joined the company’s Scientific Advisory Board. Dr. Starnbach is internationally recognized for his pioneering work on T-cell immunity to intracellular bacterial pathogens, including Chlamydia trachomatis . His research has advanced understanding of how CD8⁺ T cells recognize infected cells and contribute to immune defense ag

StiRx Co-Authors Strategic Analysis on the Evolving Strategy for Drug-Resistant Gonorrhea

Boston, MA — January 2026 — StiRx announced the publication of a peer-reviewed review article in Current Opinion in Infectious Diseases analyzing the shifting treatment paradigm for drug-resistant Neisseria gonorrhoeae . By contrasting the near-term antibiotic pipeline with longer-horizon biologic and immune-based solutions, the analysis frames a category poised for innovation as resistance undermines legacy therapies. The review highlights that while new oral antibiotics ma

StiRx Showcases Advances in Next-Generation Immunotherapeutics at ISV Congress 2025

Boston, MA – October 2025 — StiRx, a biotechnology company pioneering next-generation biologics for sexually transmitted infections...

StiRx and International Vaccine Institute (IVI) Sign Memorandum of Understanding to Advance Monoclonal Antibody Technologies Against Drug-Resistant Gonorrhea

Boston, MA, August 2025 - StiRx Inc., a biotechnology company pioneering best-in-class vaccines and biologics against sexually...